Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

PURPOSE: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Garon, Edward B., Hellmann, Matthew D., Rizvi, Naiyer A., Carcereny, Enric, Leighl, Natasha B., Ahn, Myung-Ju, Eder, Joseph Paul, Balmanoukian, Ani S., Aggarwal, Charu, Horn, Leora, Patnaik, Amita, Gubens, Matthew, Ramalingam, Suresh S., Felip, Enriqueta, Goldman, Jonathan W., Scalzo, Cathie, Jensen, Erin, Kush, Debra A., Hui, Rina
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
RAPID COMMUNICATION
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768611/
https://ncbi.nlm.nih.gov/pubmed/31154919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00934
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires